Alternate Sites of Care: The Changing Face of Healthcare Delivery

Posted by Parijat Sharma on December 23, 2019

Matthew Ruple co-authored this post with Parijat Sharma. A version of this blog post was originally published on The Active Ingredient.

A confluence of factors is driving a dramatic shift in healthcare delivery from traditional sites of care such as hospitals and clinics to outpatient and retail care sites such as urgent care clinics and ambulatory surgical centers. Of course, this shift doesn’t just change things for patients and providers. It also greatly affects the go-to-market strategies for pharmaceutical and medical device manufacturers. As the care setting evolves and diversifies, stakeholders throughout the healthcare ecosystem have to evolve in kind.


>
Read More

Despite More Sophisticated Compensation Methods, Are Medtech Companies Set Up for Success?

Posted by Varun Chodha on October 28, 2019

Life sciences companies have come a long way since the days when they relied on sales reps building relationships with healthcare providers. As the industry moves from an individual, relationship-heavy selling model to a value-based model, today’s sales reps must engage non-clinical stakeholders within hospitals and IDNs in addition to doctors and medical staff. It’s no longer just about discussing the latest features and charging a premium. Now, companies are being challenged to provide better outcomes at lower costs. On top of all this, achieving growth is harder than ever in an increasingly saturated market.


>
Read More

ACC 2019: What the Latest Procedural Advancements Might Mean for Medtech

Posted by Eric Sin on April 16, 2019

Just a couple of weekends ago, I sat in the crowd at the American College of Cardiology (ACC) conference in New Orleans as Dr. Leon and Dr. Reardon presented on transcatheter aortic valve replacement (TAVR) trials in low-surgical-risk aortic stenosis (AS) patients. These findings will not only raise paradigm-shifting questions for the AS market but also prompt discussion around some common industry dilemmas, especially for markets where effective but expensive procedure options become more widely accepted for broader patient populations.


>
Read More

What Medtech Companies Can Learn From Apple's Virtual Clinical Study

Posted by Kate Templeton on March 21, 2019

The American College of Cardiology’s (ACC) Scientific Session and Expo, held March 16-18 in New Orleans, kicked off Saturday morning with the initial results of the much-anticipated Apple Heart Study. For those who keep pace with the fast-moving tech world, I’m sure it felt like an eternity since the study had been announced. But by healthcare standards, the study went quickly and accomplished something unthinkable: It enrolled a breathtaking 419,297 individuals in eight months using a novel, entirely virtual study design.


>
Read More

Generating Value Through Digital and Connected Health Analytics

Posted by Vishal Srivastava on February 13, 2019

"Digitization" has been disrupting several parts of the economy, including the medical devices industry. Beyond the initial hype, we see several programs beginning to show real results and that look promising for improving quality and decreasing healthcare costs. The industry is beginning to look at digital health solutions to drive differentiation as it moves toward focusing on healthcare value and outcomes.


>
Read More